NCT04499157Terminated
Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients. The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.
- Status (registry)
- Terminated
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 29 Jul 2020
- Start date
- 21 Sept 2020
- Primary completion date
- 18 Jan 2024
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Diseases
- Glaucoma
- NCT number
- NCT04499157
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- diagnosis of cataract or surgery of cataract during the follow-up
- ocular hypertonia due to a secondary cause (like corticosteroids)
- general treatment affecting PIO (beta blockers, corticosteroids)
Other illness
- retinal or macular disease
- allergy to citicolin
- history of anterior, intermediate or posterior uveitis
Other
- pregnancy or breastfeeding
Who the study is looking for
- diagnosis of GCAO defined by OCT RNFL alterations and visual fields defects
- age between 20 and 80 years old
- Well controled intra-ocular pressure under treatment (PIO\<21mmHg or decreased by 20% compared to initial the PIO)
Age in the registry: 20 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Amiens Coordinator of this site? Confirm its status | Amiens | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.